vius, other Prevotella species, and peptostreptococci. 7 The polymicrobial nature of PID requires empiric therapy with a broad-spectrum antimicrobial agent or combination. 8, 9 Complicating effective therapy, however, has been the development of significant antibiotic resistance through production of penicillinase by N. gonorrhoeae and of 13- lactamase by various other causative pathogens of PID. Although combination therapy with gentamicin and clindamycin has been considered the "gold standard, ''8,11 in recent clinical trials 9,,1z the combination of the [3-1actam ampicillin and the [3- 1actamase inhibitor sulbactam has demonstrated excellent activity against pathogens associated with pelvic infections in women. 1, 4 The present study was undertaken to directly compare the efficacy and safety of ampicillin/ sulbactam and cefoxitin, a semisynthetic cephamytin, in women with PID.
SUBJECTS AND METHODS
Eligible for enrollment were females 14 years of age or older who provided informed written consent (including parental or legal guardian consent for patients <18 years of age) and who had a diagnosis of PID based on medical history, clinical laboratory findings, physical examination, and clinical signs and symptoms of infection, including abdominal, adnexal, or cervical motion tenderness. Leukocyte count ->10,000 mm", temperature -> 100. 4 No significant difference in clinical efficacy was noted between the 2 treatments (P 0.67) (Fig. 1) 21 In summary, PID, a common infection among sexually active women, may entail a significant risk of long-term sequelae, including chronic abdominal pain, ectopic pregnancy, and infertility. 22 Effective treatment of this disease requires broad antimicrobial coverage that traditionally has been achieved with relatively expensive combination therapy involving administration of as many as three agents with different dosage schedules. 23, 24 The combination of the 3-1actam ampicillin with the [3-1actamase inhibitor sulbactam has demonstrated excellent clinical and bacteriologic efficacy in patients with PID, and is less expensive than many other therapies, including cefoxitin.
